Reyon Pharmaceutical Co., Ltd.

As of June 30, 2026, Reyon Pharmaceutical Co., Ltd. carries a market capitalization of 186.34B, placing it among publicly traded companies globally. Its enterprise value stands at 396.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Reyon Pharmaceutical Co., Ltd. has 18.34M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.30, and the price-to-book ratio stands at 0.96.

As of June 30, 2026, Reyon Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 134.54 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.76 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 396.16B versus a market cap of 186.34B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Reyon Pharmaceutical Co., Ltd. maintains a current ratio of 0.50, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 111.28, indicating elevated leverage, while an interest coverage ratio of 0.21 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Reyon Pharmaceutical Co., Ltd. posted a negative return on equity (ROE) of -15.86, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.44, reflecting losses generated across the asset base. The company generates approximately 315.11M in revenue per employee across its workforce of 455.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.95 indicates how many times Reyon Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Reyon Pharmaceutical Co., Ltd. recorded 1.99B in income tax expense. The company reported a pretax loss of -32.26B and -34.24B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Reyon Pharmaceutical Co., Ltd.'s stock has declined approximately 10.24% over the past 52 weeks. The 50-day moving average sits at 10,030.60, while the 200-day moving average is 10,443.80.

Over the twelve months ended June 30, 2026, Reyon Pharmaceutical Co., Ltd. generated 143.37B in revenue and converted that into -34.24B in net income, yielding earnings per share of -1,867.12. EBITDA reached 2.94B, while operating income came in at -29.43B.

As of June 30, 2026, Reyon Pharmaceutical Co., Ltd. holds 7.04B in cash and equivalents against 216.85B in total debt, resulting in a net debt position of 207.99B. Total book value stands at 194.87B, with working capital of -79.81B providing operational flexibility.

Reyon Pharmaceutical Co., Ltd. produced 6.22B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -5.04B in capital expenditures, free cash flow totaled 1.18B - equivalent to 64.21 per share.

Over the twelve months ended June 30, 2026, Reyon Pharmaceutical Co., Ltd. posted a gross margin of 26.14, reflecting its pricing power and cost economics. The operating margin of -20.52 and net profit margin of -23.88 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.63, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.68, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Reyon Pharmaceutical Co., Ltd. shareholders.

Reyon Pharmaceutical Co., Ltd.'s most recent stock split took place on December 29, 2020 with a 50:51 split ratio.

As of June 30, 2026, Reyon Pharmaceutical Co., Ltd. has an Altman Z-Score of 0.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.